

Nifty Outlook

Markets managed to end on a strong note in an unusual session. The benchmark made a decent start, tracking favourable global cues however technical glitch on NSE halted trading for most of the session before resuming again at 3.30 pm. Sentiment boosted in the extended hours, taking note of the news that the finance minister allowed the government businesses to transact with private banks. Consequently, the Nifty index ended with strong gains of nearly 2%. Amongst the sectors, Banking was the top outperformer ending higher by 3.7% followed by Capital Goods which ended higher by 1.8%. The broader markets too participated as both BSE Midcap and Smallcap ended higher by 0.8% and 1.1%.

We expect volatility to remain high on Thursday due to the scheduled derivatives expiry of February month contracts. It would be prudent to avoid naked leveraged positions in early trades and prefer hedged bets.


	VWAP (Expiry till date)	Max OI (Call)	Max OI (Put)
NIFTY	14450	15000	14000

News

- **Granules India** announced that the US FDA has approved its Abbreviated New Drug Application for Acetaminophen, Aspirin and Caffeine Tablets USP, 250 mg/250 mg/65 mg (OTC).
- **Strides Pharma Science** announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Ibuprofen Oral Suspension USP, 100 mg/5 mL (OTC) from USFDA.
- **Bharti Airtel** has entered the advertising business with the launch of Airtel Ads. Airtel Ads allows brands of all sizes to curate consent based and privacy safe campaigns to one of the biggest pool of quality customers in India.

Derivative Ideas **					
Instrument	B/S	Lot	INITIATION RANGE	SL	TARGET
APOLLOTYRE	BUY	CASH	231-233	223	247

Sectors to watch	
Sector Name	Outlook
IT	BULLISH
BANKS	STABLE
FMCG	STABLE



Religare Super Idea**

Scrip	Buy/Sell	CMP	Initiation Range	SL*	Target
MUTHOOTFIN	BUY	1293.50	1270-1280	1230	1370

**Please note that the given technical and derivative recommendations are "valid for taking position" only on recommended date and in the given range.

*Please note - Stoploss is on closing basis for delivery recommendation and intraday basis for F/O recommendation.

FII & DII Cash Segment (Rs. in Cr.)			
Category	Amt.	MTD	FYTD
FII**	-1569	21412	179939
DII**	217	-17341	-137731

Trade Stats		
	NO OF CONTRACTS	TURNOVER IN CR
IDXFUTS	437900	43211
IDXOPT	27278439	11299
STKFUTS	1057250	96286

**Provisional data as on 23rd February, 2021

Derivative Ideas

APOLLOTYRE FUTS added around 12% in open interest addition as LONG buildup was seen in it till closing time. Current chart pattern also indicates further up move in its price. We suggest buying APOLLOTYRE as per below levels.

Strategy:- BUY APOLLOTYRE BETWEEN 231-233 STOPLOSS AT 223 TARGET 247.

Investment Pick - Britannia Industries Ltd.

Scrip	CMP	Recommendation Price	Target	Duration
Britannia Industries Ltd.	3,405.55	3,462	4,265	9-12 Months

Britannia Industries (BRIT) posted mixed numbers wherein revenue was below our expectation while profit grew strong. Revenue came in at Rs 3165.6cr, up by 6.1% YoY. On operational front, its EBITDA grew by 21.7% YoY to Rs 611.5cr, while margin expanded by 248bps on the back of cost efficiencies measures. The company reported healthy growth of 22.4% YoY in net profit at Rs 452.6cr with margin expansion of 190bps YoY to 14.3%. Going forward, we remain positive on the company's long term growth as the focus would be enhancing sales, improving margins via cost efficiency measures and strengthening distribution reach. Maintain a Buy.

Going forward, BRIT strategy would be to drive strong growth by launching new and innovating products, focus on brand building and strengthening distribution reach. Besides its efforts on improving margins via cost efficiency would be its core agenda. Apart from this, strong growth momentum from rural and international businesses will continue to support and lead to market share gains. Further along with the optimistic management plan the company has strong balance and decent cash flow which would aid growth. Thus, we have a positive view on the stock for long term and have maintained a buy rating on the stock with a target price of Rs 4,265.

CACT Calendar - February 2021 (Buy Back of Shares)

Sun	Mon	Tue	Wed	Thu	Fri	Sat
21	22	23 • Niit Ltd.	24	25 • Gujarat Apollo Industries Ltd.	26 • Smartlink Holdings Ltd.	27

Economic Calendar - February 2021

Sun	Mon	Tue	Wed	Thu	Fri	Sat
21	22	23	24	25	26 <ul style="list-style-type: none"> Federal Fiscal Deficit (Jan) GDP Annual GDP Quarterly (YoY) (Q3) Infrastructure Output (YoY) (Jan) 	27

CACT Calendar - February 2021 (Cash Dividend)

Su	Mon	Tue	Wed	Thu	Fri	Sat
21	22	23	24	25	26	27
	<ul style="list-style-type: none"> Aurobindo Pharma Ltd. Dcm Shriram Industries Ltd. Goldiam International Ltd. Itc Ltd. Mazagon Dock Shipbuilders Ltd Mercury Laboratories Ltd Natco Pharma Ltd. Nhpc Ltd. Panchsheel Organics Ltd. Selan Exploration Technology Ltd. Shanthi Gears Ltd. Tube Investments Of India Ltd 	<ul style="list-style-type: none"> Cochin Shipyard Ltd Ircon International Ltd Oil India Ltd. Precision Wires India Ltd. Sjvn Ltd Tower Infrastructure Trust United Drilling Tools Ltd. Zuari Global Ltd. 	<ul style="list-style-type: none"> Isgec Heavy Engineering Ltd Karda Constructions Ltd Nile Ltd. Racl Geartech Ltd Sandhar Technologies Ltd Techno Electric & Engineering Company Ltd 	<ul style="list-style-type: none"> Amara Raja Batteries Ltd. Career Point Ltd. Dharamsi Morarji Chemical Co.Ltd. G M Polyplast Ltd The Yamuna Syndicate Ltd 		

CACT Calendar - February 2021 (Right Issue of Equity Shares)

Sun	Mon	Tue	Wed	Thu	Fri	Sat
21	22	23	24	25	26	27
		<ul style="list-style-type: none"> Arvind Fashions Ltd 				

CACT Calendar - February 2021 (Bonus Issue 5:8)

Sun	Mon	Tue	Wed	Thu	Fri	Sat
21	22	23	24	25	26	27
				<ul style="list-style-type: none"> Nakoda Group Of Industries Ltd 		

Result Calendar - February 2021

Sun	Mon	Tue	Wed	Thu	Fri	Sat
21	22	23	24	25	26	27
<ul style="list-style-type: none"> India Finsec Ltd. Uniply Decor Ltd Uniply Industries Ltd. 	<ul style="list-style-type: none"> Apoorva Leasing Finance And Investment Company Ltd Spel Semiconductor Ltd. 	<ul style="list-style-type: none"> Elantas Beck India Ltd. Sanofi India Ltd Stove Kraft Ltd Uniply Decor Ltd Uniply Industries Ltd. 	<ul style="list-style-type: none"> Aananda Lakshmi Spinning Mills Ltd Asya Infosoft Limited Huhtamaki India Ltd Indianivesh Ltd. 	<ul style="list-style-type: none"> Ksb Ltd Rain Industries Ltd Vesuvius India Ltd. 	<ul style="list-style-type: none"> Alliance Integrated Metaliks Ltd. Abb Power Products And Systems India Ltd Stovec Industries Ltd. 	

Religare Investment Calls

Name of the Company	Reco Date	Current Rating*	Product Type	Reco Price	Target Price	Upside %	CMP	Expected returns from CMP %
Godrej Agrovet	13-Feb-2020	Buy	Investment Call	559	618	10.5%	484	27.6%
INOX Leisure	20-Aug-2020	Buy	High Conviction Ideas	282	376	33.3%	314	19.8%
Godrej Consumer Products	16-Sept-2020	Buy	Investment Call	706	845	19.7%	693	22.0%
Bharti Airtel	09-Nov-2020	Buy	High Conviction Ideas / Diwali Picks	450	709	57.6%	573	23.7%
Sudarshan Chemical Industries	09-Nov-2020	Hold	Diwali Picks	442	583	31.9%	533	9.4%
Coromandel International	28-Dec-2020	Buy	New Year Picks 2021	802	978	21.9%	762	28.3%
JK Lakshmi Cement	28-Dec-2020	Buy	New Year Picks 2021	337	428	27.0%	369	15.9%
Manappuram Finance	28-Dec-2020	Buy	New Year Picks 2021	164	205	25.0%	172	19.3%
Natco Pharma	28-Dec-2020	Buy	New Year Picks 2021	932	1,135	21.8%	806	40.9%
SBI Life Insurance	28-Dec-2020	Buy	New Year Picks 2021	874	1,069	22.3%	872	22.7%
Dabur India	04-Feb-2021	Buy	High Conviction Ideas	525	616	17.3%	504	22.3%
Castrol India	09-Feb-2021	Buy	Investment Call	134	148	10.4%	125	18.4%
Britannia Industries	10-Feb-2021	Buy	High Conviction Ideas	3,462	4,265	23.2%	3,406	25.2%

*Current rating is based on returns potential

Buy - Potential Returns $\geq 10\%$ over 12 months

Hold - Potential Returns $\leq 10\%$ over 12 months

For Religare Investment calls performance [click here](#)

Research Product Basket

- For every client, the advisor must allocate a specific proportion of funds for trading and investing depending on the risk taking ability and willingness of the client and their investment goals.
- The below mentioned product basket tries to address the way to deal with the trading portfolio (cash/derivative) for optimum effectiveness of research calls.
- It is recommended to divide your trading funds for various types of calls and not invest the entire amount for 1 or 2 calls only.

For cash market trading					For 1L margin*	
Call / Product	Call Frequency	No. of calls	Avg open call duration	% funds allocated	Total	Per Call
Intraday Calls	Intraday	2 - 3	< 1 day	25%	25,000	8,000
Live / RMD Calls	Daily	3 - 4	3 - 4 days	30%	30,000	4,000
Master Pick	Weekly	1	1 month	15%	15,000	5,000
Religare Alpha	Opportunity	NA	2 - 3 months	20%	20,000	As per weightage
Cash		NA		10%	10,000	
Intraday Calls	These calls are flashed live on Ms Lync and ODIN with the purpose of squaring off positions on the same day. As a policy, we restrict our intraday cash market calls to less than 4 calls a day. Hence, funds should be allocated accordingly to have provision to trade in all calls.					
Live / RMD Calls	2 super ideas are flashed in RMD daily with a view of 3-4 days. Additionally as per market opportunity, we flash live calls during the day (including BTST calls). 3-4 such calls are made on a daily basis which might be open for 3-4 days. Funds should be allocated keeping in mind that there will be 7-8 such open calls daily.					
Master Pick	This is our weekly recommendation shortlisted on the basis of techno-funda analysis. 15% of funds is recommended to be allocated for Master Pick considering that there will be 3 open calls. The average open duration for this call will be 1 month.					
Religare Alpha	This is a portfolio of 8-10 stocks which are held with a view of 2-3 months. It is recommended to allocate 20% of funds for building this portfolio which will provide stability to the overall trading portfolio.					
Cash	10% surplus cash in the portfolio should be kept for the purposes of allocating it to opportunities as and when they arrive.					

For derivative market trading					For 1L margin*	
Call / Product	Call Frequency	No. of calls	Avg open call duration	% funds allocated	Total	Per Call
Derivative Ideas	Daily	1 - 2	1 - 3 days	40%	40,000	40,000
Live calls	Intraday / Daily	1 - 2	3 - 4 days	50%	50,000	50,000
Cash		NA		10%	10,000	
Derivative Ideas	1 derivative idea is shared in RMD daily. It can be a plain vanilla F&O buy/sell call or an option strategy. Funds should be allocated assuming 2 such calls will be open at any time. These calls are open for 3-4 days on an average.					
Live Calls	These calls are flashed on MS Lync and ODIN during live market hours. These calls can be intraday or with a view of 2-3 days. Funds should be allocated considering 2 such calls will be open at any time. 3/4 times, these calls will be on Nifty / Bank Nifty only.					
Cash	It is recommended to hold 10% cash to capitalize on any opportunity that may arise in markets.					

Research Analysts

Ajit Mishra	ajit.mishra@religare.com
Himanshu Sharma	himanshu.sharma1@religare.com
Manoj M Vayalar	manoj.vayalar@religare.com
Nirvi Ashar	nirvi.ashar@religare.com
Rohit Khatri	rohit.khatri@religare.com
Suhanee Shome	suhanee.shome@religare.com

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link : <https://www.religareonline.com/disclaimer>

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation- Research Analyst (RA)

[Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F (a) to F(j) below, are given separately]

S. No.	Statement	Answer	
		Yes	No
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one per cent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No

	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No
	I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No

	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Nature of Interest (if answer to F (a) above is Yes:

Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F (a) to F(j) above, are given below]

SS.No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No.

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results"